Best of WCLC24 by Noemi Reguart

WCLC is a prominent global conference dedicated to the latest developments in lung cancer research, treatment, and patient care. Hosted by the International Association for the Study of Lung Cancer (IASLC), the event gathers researchers, clinicians, and healthcare professionals to exchange knowledge, explore new innovations, and work together on strategies to enhance lung cancer patient outcomes.

This year, WCLC24 is taking place in San Diego from September 7th to 10th. Dr. Noemi Reguart  has shared multiple updates about the conference on her X account:

Key results of IDeate-Lung01 study

“First WCLC24 Press Conference Charlie Rudin presenting key results of IDeate-Lung01 study to be presented tomorrow!! Do not miss OA04.03 Ifinatamab Deruxtecan (I-DXd, B7H3) in ES-SCLC Interim Analysis results at 8 and 12 mg/kg: promising ORR 26% and 55%; PFS 4.2 and 5.5 months.”

Opening session at WCLC24

“Opening session at WCLC24 presented by the chairs Sandip Patel, Narjust Florez, Linda Martin, Fabio Moraes, president Dr. Paul Van Schil and CEO Karen Kelly. Very emotionally touching talk by Tomasa Ramirez and her daughter, our beloved Narjust.”

Research and Early Detection awards

“Congratulations to all our friends Julie Brahme, Erik Thunnissen and Claudia Henschke for receiving the prestigious Research and Early Detection awards. A history of success paving the future and present of lung cancer, well deserved recognition.”

A powerful awareness call

“My friend and colleague Dr. Oscar Arrieta giving a powerfull talk in the opening ceremony at WCLC24. A powerful awareness call on the disparity in drug access in Mexico and Latinoamerica.”

PRESIDENTIAL. P3

“PRESIDENTIAL. P3 Ivonescimab (AK112) vs. Pembro as 1L for PD-L1+ aNSCLC: PA of HARMONi-2. mPFS 11.14 vs 5.82 HR 0.51, p < 0.0001. 1st trial demostrating a significant improvement with a novel drug compound vs. pembro. Awaiting OS and comfirmatory data outside China.”

PRESIDENTIAL 1

“PRESIDENTIAL 1 WCLC24 Exploratory Normalized Membrane Ratio (NMR) of TROP2 by Quantitative Continuous Scoring (QCS) predictive of Outcomes in TROPION-Lung 01 Marina Garassino. Thought-provoking concept but still far from being implemented in RW.”

KEYNOTE-671

Association of Pathologic Regression with EFS in the KEYNOTE-671. Median % RVT 29.5% pembro arm vs 52% in the plb. As expected higher % RVT associated with poorer EFS.

Noemi Reguart is a Medical Oncologist at Hospital Clinic Barcelona. Prof. Reguart’s work focuses on translational genomics and targeted therapies in lung cancer. Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. She is an active member of several international organizations including the Lung Cancer Group of the European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), and the International Association for the Study of Lung Cancer (IASLC). 

For more updates on WCLC24, visit oncodaily.com.